The Clinical Value of Genetic Testing in Lung Squamous Cell Carcinoma: A Retrospective Study

Why It Matters

The study demonstrates that routine genomic profiling can transform LSCC management by enabling effective, less toxic, and cost‑saving targeted therapies, especially for demographic groups with higher mutation prevalence.

Key Takeaways

• 19.2% driver mutation detection in tested LSCC patients
• EGFR mutations prevalent in non‑smokers (66.7% of cases)
• Targeted therapy reduced severe adverse events to 4.7%
• Younger, female, non‑smoker patients show higher mutation rates
• Targeted treatment improved progression‑free survival and lowered costs

Pulse Analysis

Lung squamous cell carcinoma (LSCC) accounts for roughly 30% of all non‑small cell lung cancers and has traditionally been managed with chemotherapy and radiotherapy rather than molecularly driven approaches. In recent years, the rise of precision oncology has prompted clinicians to explore whether the genomic landscape of LSCC can be leveraged for targeted interventions, as has been successful in adenocarcinoma subtypes. However, data on the prevalence of actionable driver mutations and the clinical payoff of routine genetic testing in LSCC remain limited, especially in Asian populations where smoking patterns differ.

The retrospective analysis of 1,515 LSCC patients from Chongqing University Cancer Hospital revealed a 19.2% overall detection rate of driver mutations among the 292 individuals who underwent testing. EGFR emerged as the most common alteration (26 cases), with a striking 66.7% prevalence among non‑smokers, while MET accounted for ten mutations. Subgroup analysis showed higher mutation frequencies in patients ≤65 years, females, and never‑smokers. Importantly, those receiving genotype‑matched targeted therapy experienced superior objective response rates, disease control, and median progression‑free survival, while severe grade 3–4 toxicities dropped from 40% to 4.7%.

From a health‑economics perspective, the study reported a negative incremental cost‑effectiveness ratio, indicating that targeted regimens not only extended survival but also reduced overall treatment expenditures compared with standard chemotherapy. These findings support integrating routine next‑generation sequencing into LSCC diagnostic pathways, particularly for younger, female and never‑smoker cohorts who are most likely to harbor actionable alterations. As payer policies evolve, clinicians should advocate for broader insurance coverage of molecular profiling, enabling earlier adoption of precision medicines and potentially reshaping the therapeutic landscape of squamous lung cancer.